Female genital tract secretions inhibit herpes simplex virus infection: correlation with soluble mucosal immune mediators and impact of hormonal contraception
- PMID: 20015330
- PMCID: PMC4418527
- DOI: 10.1111/j.1600-0897.2009.00768.x
Female genital tract secretions inhibit herpes simplex virus infection: correlation with soluble mucosal immune mediators and impact of hormonal contraception
Erratum in
- Am J Reprod Immunol.2010 May 1;63(5):410. Dosage error in article text
Abstract
Problem: Female genital tract secretions inhibit herpes simplex virus (HSV) infection, however, the intra- and inter-subject variability, contribution of specific mediators, and impact of reproductive hormones have not been defined.
Method: of study Cervicovaginal lavage (CVL) (n = 89) obtained from nine cyclers and seven women on hormonal contraception (HC), who completed between three and eight weekly visits, were examined for anti-herpes simplex virus activity and concentrations of mediators.
Results: The CVL inhibited HSV infection by a mean value of approximately 57% during the follicular or luteal phase, but only by 36% in hormonal contraceptive users. Human neutrophil peptides 1-3 (HNP1-3) (P = 0.03), IL-8 (P = 0.003), lactoferrin (P = 0.005), lysozyme (P = 0.003), IgA (P = 0.002), and IgG (P = 0.02) correlated with antiviral activity. Intra-subject and inter-subject variability was observed, suggesting that factors other than hormones contribute to innate defense.
Conclusion: Endogenous antimicrobial activity may provide a biomarker of healthy mucosal immunity and may be reduced in the setting of HC. However, larger prospective studies are needed.
Figures


Similar articles
-
The effect of menopause on the innate antiviral activity of cervicovaginal lavage.Am J Obstet Gynecol. 2015 Aug;213(2):204.e1-6. doi: 10.1016/j.ajog.2015.03.045. Epub 2015 Mar 25. Am J Obstet Gynecol. 2015. PMID: 25818668 Free PMC article.
-
Novel Role for Interleukin-17 in Enhancing Type 1 Helper T Cell Immunity in the Female Genital Tract following Mucosal Herpes Simplex Virus 2 Vaccination.J Virol. 2017 Nov 14;91(23):e01234-17. doi: 10.1128/JVI.01234-17. Print 2017 Dec 1. J Virol. 2017. PMID: 28956763 Free PMC article.
-
Cervicovaginal secretions contribute to innate resistance to herpes simplex virus infection.J Infect Dis. 2005 Nov 15;192(10):1731-40. doi: 10.1086/497168. Epub 2005 Oct 13. J Infect Dis. 2005. PMID: 16235171
-
Role of mucosal immunity in preventing genital herpes infection.Viral Immunol. 2005;18(4):595-606. doi: 10.1089/vim.2005.18.595. Viral Immunol. 2005. PMID: 16359226 Review.
-
Vaginal immunity in the HSV-2 mouse model.Int Rev Immunol. 2003 Jan-Feb;22(1):43-63. doi: 10.1080/08830180305228. Int Rev Immunol. 2003. PMID: 12710503 Review.
Cited by
-
Longitudinal Assessment of Systemic and Genital Tract Inflammatory Markers and Endogenous Genital Tract E. coli Inhibitory Activity in HIV-Infected and Uninfected Women.Am J Reprod Immunol. 2016 Jun;75(6):631-42. doi: 10.1111/aji.12518. Epub 2016 May 5. Am J Reprod Immunol. 2016. PMID: 27145926 Free PMC article.
-
Changes in the soluble mucosal immune environment during genital herpes outbreaks.J Acquir Immune Defic Syndr. 2012 Oct 1;61(2):194-202. doi: 10.1097/QAI.0b013e31826867ae. J Acquir Immune Defic Syndr. 2012. PMID: 22820806 Free PMC article.
-
A randomized trial to assess anti-HIV activity in female genital tract secretions and soluble mucosal immunity following application of 1% tenofovir gel.PLoS One. 2011 Jan 25;6(1):e16475. doi: 10.1371/journal.pone.0016475. PLoS One. 2011. PMID: 21283552 Free PMC article. Clinical Trial.
-
Plasma and mucosal HIV viral loads are associated with genital tract inflammation in HIV-infected women.J Acquir Immune Defic Syndr. 2013 Aug 1;63(4):485-93. doi: 10.1097/QAI.0b013e3182961cfc. J Acquir Immune Defic Syndr. 2013. PMID: 23591635 Free PMC article.
-
Postcoital bioavailability and antiviral activity of 0.5% PRO 2000 gel: implications for future microbicide clinical trials.PLoS One. 2010 Jan 22;5(1):e8781. doi: 10.1371/journal.pone.0008781. PLoS One. 2010. PMID: 20107502 Free PMC article.
References
-
- Xu F, Sternberg MR, Kottiri BJ, McQuillan GM, Lee FK, Nahmias AJ, Berman SM, Markowitz LE. Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. JAMA. 2006;296:964–973. - PubMed
-
- Nagot N, Ouedraogo A, Konate I, Weiss HA, Foulongne V, Defer MC, Sanon A, Becquart P, Segondy M, Sawadogo A, Van de Perre P, Mayaud P. Roles of Clinical and Subclinical Reactivated Herpes Simplex Virus Type 2 Infection and Human Immunodeficiency Virus Type 1 (HIV-1)-Induced Immunosuppression on Genital and Plasma HIV-1 Levels. J Infect Dis. 2008;198:241–249. - PubMed
-
- Freeman EE, Weiss HA, Glynn JR, Cross PL, Whitworth JA, Hayes RJ. Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. Aids. 2006;20:73–83. - PubMed
-
- Mertz GJ, Benedetti J, Ashley R, Selke SA, Corey L. Risk factors for the sexual transmission of genital herpes. Ann Intern Med. 1992;116:197–202. - PubMed
-
- Moss GB, Clemetson D, D’Costa L, Plummer FA, Ndinya-Achola JO, Reilly M, Holmes KK, Piot P, Maitha GM, Hillier SL, et al. Association of cervical ectopy with heterosexual transmission of human immunodeficiency virus: results of a study of couples in Nairobi, Kenya. J Infect Dis. 1991;164:588–591. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous